Newsletter

Int. Rev. Allergol. Clin. Immunol. Family Med., 2018, XXIV/3: 093-099 Maximize

Int. Rev. Allergol. Clin. Immunol. Family Med., 2018, XXIV/3: 093-099

Title: Azithromycin in therapy of patients with borreliosis 

Author: Płusa T. 

More details

01-03-2018

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Azithromycin in therapy of patients with borreliosis

Płusa T.

Medical Faculty of Łazarski Univdersity of Warsaw, Poland

Int Rev Allergol Clin Immunol Family Med, 2018; Vol. 24, No. 3, 093

The treatment of patients with Lyme disease is based on recommendations based on data from 20 years ago. The effectiveness of antibiotic therapy is debatable, as more and more cases and complications are still observed. Available new studies and clinical analyzes indicate the possibility of using other groups of antibiotics than those used so far, since the nature of the infection and its course can be effectively controlled from the first step of infection. Azithromycin fulfills such expectations, because its pharmacokinetic parameters and the bacteriological spectrum enable combating the infection caused by Borrelia burgdorferi. The proposed application of the cream with 4% azithromycin in the first stage of treatment and the oral administration of the antibiotic in intracellular forms, causes the inhibition of the spread of infection and destruction of bacteria. The effectiveness of azithromycin in controlling the biofilm produced by borellia, in addition to the broad spectrum of immunomodulatory properties, indicates the need to verify the current therapeutic recommendations in patients with Lyme disease.

Key words: azithromycin, Lyme disease